Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
Year: 1998
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet
Institutions: Centre National de la Recherche Scientifique, Sorbonne Université, Pitié-Salpêtrière Hospital, Université Pierre-et-Marie-Curie, Hôpital Beaujon, University of Calgary, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf, University of Manitoba, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, University of Alberta, Goethe University Frankfurt, University Hospital Frankfurt, Hospices Civils de Lyon, Hôtel-Dieu de Lyon
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2165715544